bluebird bio, Inc. announced that new data from its ongoing Phase 1/II HGB-206 study of investigational LentiGlobin gene therapy for adult and adolescent patients with sickle cell disease… read more.
Omeros Corporation announced that the results of its pivotal trial of OMS 721 (narsoplimab) in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) demonstrating that targeted… read more.
NICE has published draft guidelines rejecting use of a combination drug therapy containing Sarclisa (isatuximab), from Sanofi, plus pomalidomide and dexamethasone (pom-dex), to treat multiple myeloma within the… read more.
Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/IIa first-in-human clinical trial of its investigational SARS-CoV-2 vaccine,… read more.
Mallinckrodt Plc announced publication of findings from a medical chart study to assess the real-world use of terlipressin and other vasopressors in hospitalized patients with hepatorenal syndrome type… read more.
Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/IIa first-in-human clinical trial of its investigational SARS-CoV-2 vaccine,… read more.
Otsuka Pharmaceutical has announced positive top-line results from two, six-week, phase III clinical trials that evaluated the efficacy, safety and tolerability of oral EB 1020 (centanafadine), a novel… read more.
Viela Bio announced that the FDA has approved Uplizna (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive as… read more.
Impel NeuroPharma announced positive results from “STOP 301” (Safety and Tolerability of POD-DHE), the Company’s pivotal Phase III, open-label study of the safety and tolerability of INP 104… read more.
AbbVie announced new long-term results showing that once-daily Rinvoq (upadacitinib) continued to improve signs and symptoms in patients with rheumatoid arthritis at 72 and 84 weeks in the… read more.
Fulcrum Therapeutics, Inc. announced plans to evaluate losmapimod as a potential treatment for patients with COVID-19 . Fulcrum has submitted an investigational new drug (IND) application to support… read more.
Mallinckrodt Plc announced that Stratatech, a Mallinckrodt company, has completed its rolling submission of a Biologics License Application (BLA) to the FDA for StrataGraft, a regenerative skin tissue… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
